BostonGeneCorp

A biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients.

[BostonGeneCorp @BostonGeneCorp]

We are pleased to announce a strategic collaboration with @ImmunoGenesis_ to accelerate the clinical development of IMGS-001, a novel cytotoxic dual checkpoint inhibitor targeting PD-L1 and PD-L2.

This partnership integrates BostonGene’s AI-driven multiomics and high-resolution spatial biology into the Phase 1a/b clinical framework to move beyond conventional monitoring. By leveraging our AI foundation model, this collaboration is designed to elucidate MoA, identify predictive biomarkers and optimize patient selection.

Together, we are working to eliminate the "trial and error" approach often associated with immunotherapy. By decoding the precise cellular and molecular pathways driving clinical outcomes, we are ensuring that next-generation therapies reach the patients who need them most with greater speed and clinical certainty.

Read more: https://t.co/H8gslJGM6g

[BostonGeneCorp @BostonGeneCorp]

We are thrilled to announce a strategic partnership between BostonGene and @Unilever! By combining BostonGene’s advanced AI foundation models and multiomics research with Unilever’s world-class scientific expertise, we are exploring the biological factors that make every individual unique.

This collaboration extends our technology beyond oncology into the broader realm of human biology. Together, we’re uncovering insights that will inspire the next generation of consumer-focused, science-based innovations.

Read more: https://t.co/O6QS4CXjGB

[BostonGeneCorp @BostonGeneCorp]

We’re excited to collaborate with @DaiichiSankyoUS to accelerate drug development through AI-driven multimodal analytics. By integrating BostonGene’s translational intelligence platform into the core of an ADC development program of Daiichi Sankyo, we’re generating digital twin models from hundreds of thousands of patient profiles to better understand the biological signals that distinguish responders from non-responders.

This collaboration is focused on enabling earlier, more confident development decisions - reducing uncertainty and helping bring differentiated therapies to patients with cancer faster.

Read more: https://t.co/PsyCexAAwz

[BostonGeneCorp @BostonGeneCorp]

The latest independent validation study in Modern Pathology reinforces the technical rigor and real-world relevance of BostonGene’s AI-driven approach.

By evaluating AI methods under a stringent, multi-site framework, this study mirrors the benchmarks used by drug developers and regulators to assess advanced analytics. This publication adds to the growing body of evidence positioning BostonGene among a select group of companies operating at the highest threshold of scientific and technical excellence.

“This is not an isolated result. We continue to see independent, external validation of the AI and ML algorithms that power our foundation model. These blinded, real-world evaluations provide the high-stakes certainty that drug developers trust when accelerating life-saving therapies.” - Nathan Fowler, MD, Chief Medical Officer at BostonGene.

Read more: https://t.co/flOAwLNVlb

[BostonGeneCorp @BostonGeneCorp]

We’re heading to #IO360 to showcase how our natively AI-powered omnimodal foundation model is accelerating drug development. We’re excited to discuss how our biologically grounded AI helps partners:

- Accelerate timelines by identifying early efficacy signals.
- De-risk trials through predictive safety and response modeling.
-Optimize patient selection with tumor and immune profiling.

From refining biomarker strategies to advancing first-in-class therapies, we provide the clarity needed to increase your probability of clinical success.

Email [email protected] to schedule a meeting onsite!

#IO360 #ImmunoOncology #DrugDevelopment #AI

[BostonGeneCorp @BostonGeneCorp]

We are honored to be recognized by @Frost_Sullivan with the 2025 Global Technology Innovation Leadership Award in the AI-driven Precision Oncology Solutions sector.

This recognition highlights our commitment to redefining the drug development landscape through our natively AI-powered omnimodal foundation model for tumor and immune biology.

”BostonGene has developed state-of-the-art AI-driven, next-generation analytics technologies and is the only known source capable of delivering such comprehensive and integrated analyses. By turning vast, complex datasets into actionable insights with speed and rigor, BostonGene demonstrates dual strengths as a scientific innovator and a commercially agile partner for the global pharmaceutical industry”. - Unmesh Lal, Healthcare Research Director at Frost & Sullivan.

Read more: https://t.co/kcoOQxRTRp

[BostonGeneCorp @BostonGeneCorp]

We're very excited to partner with Ottimo Pharma to optimize and accelerate the development of their first-in-class PD-1 / VEGFR2 bifunctional therapy! We will leverage our AI-powered platform and omnimodal analytics to provide deep molecular insights, helping to deliver predictive insights on patient-level safety and efficacy outcomes in early clinical trials.

“The challenge of immune resistance in cancer treatment requires clinically precise solutions that address not only immune suppression, but also immune exclusion. OTP-01’s novel dual mechanism is designed to address both by combining immune checkpoint blockade with VEGFR2-targeted vascular normalizing activity to improve immune cell access and enable more effective antitumor immune responses. Our collaboration with BostonGene provides a promising opportunity to establish a robust, data-driven development blueprint by helping us identify the patients most likely to benefit from this differentiated therapy.” - Robert Tighe, SVP Preclinical and Translational Sciences at Ottimo Pharma

Read more: https://t.co/cRCe2XfXbr

[BostonGeneCorp @BostonGeneCorp]

We are excited to partner with @AstraZeneca to advance foundation model-driven oncology development. By leveraging BostonGene’s AI-powered platform and omnimodal analytics, this collaboration will accelerate development timelines and provide predictive insights into patient response dynamics. This initiative demonstrates the transformative power of foundation models in real-world clinical development, enabling more adaptive and biomarker-informed strategies.

“BostonGene’s platform combines deep biological insights with advanced AI and this collaboration will empower us to predict which patients will benefit from treatment helping us design safer, more effective therapies from the start. At AstraZeneca, we are focused on leveraging the vast and unparalleled potential of AI to accelerate clinical development and the delivery of innovative medicines to patients.” - Jorge Reis-Filho, MD, PhD, Chief of AI for Science Innovation, Enterprise AI Unit, AstraZeneca.

Read more: https://t.co/3X89YlJ2e1

[BostonGeneCorp @BostonGeneCorp]

“We are honored that BioTech Breakthrough (@BioTech_Awards) recognized us with ‘Overall Immunology Company of the Year.’ We saw how traditional methods were limiting the effective use of immune checkpoint inhibitors (ICIs), which, while transformative in cancer treatment, are only effective in a subset of patients.

Our platform makes personalized treatment and response monitoring a reality from a single tube of blood ... This platform not only enables personalized care—it empowers drug developers to make faster, smarter decisions grounded in real biology.” - Andrew Feinberg, President & CEO at BostonGene

Read more: https://t.co/mGviuy3ocq

[BostonGeneCorp @BostonGeneCorp]

We're gearing up for a busy #ASH25! The BostonGene team is excited to showcase the transformative power of our AI-driven profiling solutions. We are proud to present six abstracts in total—including two selected for oral presentation!

Our research highlights how AI-powered multimodal profiling is accelerating mechanism discovery, optimizing patient stratification and driving biomarker-driven therapeutic development across hematologic malignancies!

We look forward to sharing these critical insights and discussing how they can strengthen your development strategy. Email [email protected] to schedule a meeting with us onsite!

[BostonGeneCorp @BostonGeneCorp]

Join us at 4:25 PM at the #AMP2025 Innovation Spotlight Stage #2!

BostonGene’s VP of R&D, Michael Goldberg and Dr. C. Ola Landgren, M.D., Ph.D. of the Sylvester Comprehensive Cancer Center, University of Miami, will host the session “AI-Data-Driven Trial Design: Advanced Digital Models and Multimodal Testing Tools.”

They’ll explore how BostonGene’s omnimodal foundation model integrates genomic, transcriptomic, and immune data to identify patient subgroups, guide biomarker discovery, and inform treatment strategies. By applying AI-driven analysis and digital-twin approaches, BostonGene brings greater precision, adaptability and efficiency to trial design.

[BostonGeneCorp @BostonGeneCorp]

We’re excited to announce our collaboration with @KyotoU_News to develop advanced biological signatures that enhance targeted treatment strategies for patients with esophageal squamous cell carcinoma (ESCC). By combining BostonGene’s AI-powered, multi-scale, omnimodal platform with Kyoto University’s clinical expertise, we are identifying predictive biomarkers that drive innovation in drug development, clinical trial design, and improved patient outcomes.

"Understanding the molecular and immune characteristics of ESCC is essential for developing more effective treatment strategies. Through this collaboration, we will apply cutting-edge AI-powered analytics to clinical data, enabling us to identify biomarkers that can directly inform treatment decisions and improve patient outcomes." - Dr. Manabu Muto, Professor at Kyoto University and Principal Investigator of the NOBEL trial

Learn more: https://t.co/N1kM1qGzpN

[BostonGeneCorp @BostonGeneCorp]

Join us at the Society for Immunotherapy of Cancer (@sitcancer ) 40th Anniversary Annual Meeting on November 7-8! We’ll be showcasing how our omnimodal foundation AI platform advances biomarker discovery, predicts immune response and toxicity and uncovers resistance mechanisms across cancers. #SITC2025

Stop by booth 319!

[BostonGeneCorp @BostonGeneCorp]

Join us next week at #AMPath2025 for where we will host a session, "AI-Data-Driven Trial Design: Advanced Digital Models and Multimodal Testing Tools,” in collaboration with @SylvesterCancer, part of the University of Miami Health System and the Miller School of Medicine.

Discover how omnimodal platforms enhance predictions to enable targeted trials that accelerate drug development—shaping the next generation of data-driven clinical research and advancing the promise of personalized medicine.

Learn more: https://t.co/PHjsrRTWse

[BostonGeneCorp @BostonGeneCorp]

Meet us next week at the @sitcancer 40th Anniversary Annual Meeting, where we’ll showcase our research demonstrating how our omnimodal foundation AI advances biomarker discovery, predicts immune response and toxicity and reveals resistance mechanisms across cancer types. #SITC2025

Learn more: https://t.co/2ZobIST9sv

[BostonGeneCorp @BostonGeneCorp]

Join us on November 5 for the 21st Annual Industry/Academia Precision Oncology & RadMed Symposium.

During the symposium, Nathan Fowler, MD, Chief Medical Officer at BostonGene will present “Omnimodal AI for Precision Oncology: Integrating Data to Drive Discovery.”

Dr. Fowler will highlight how BostonGene’s foundation model integrates genomic, transcriptomic, immune and clinical data to generate biologically grounded insights that drive discovery, inform therapeutic development and improve patient outcomes.

Learn more: https://t.co/nuRnUrgEu2

[BostonGeneCorp @BostonGeneCorp]

BostonGene is proud to be honored with five 2025 Stevie® Awards for Technology Excellence! Our Foundation Model of Cancer and the Immune System–Led Approach was recognized for advancing precision oncology and helping biopharma de-risk drug development.

Gold Stevie® Winners
- Biomarker Discovery Platform: Technical Innovation of the Year – Biotechnology

- Target Analysis Solution: - Technology Breakthrough of the Year – Biotechnology

Silver Stevie® Winners
- End-to-End Drug Repurposing Solutions: New Product of the Year – Healthcare Technology

- Biomarker Discovery Platform: Technical Innovation of the Year – Healthcare Technology

- Target Analysis Solution: Technology Breakthrough of the Year – Healthcare Technology

Read more: https://t.co/iu1CJ80GMK

[BostonGeneCorp @BostonGeneCorp]

We’re excited to share how BostonGene’s multimodal AI is transforming cancer research and patient care, helping partners design smarter trials, uncover new targets and improve therapeutic response prediction across all stages of development.

Meet us at #ESMO25 to learn more. #AI

[BostonGeneCorp @BostonGeneCorp]

Join us this week at #ESMO25 as we showcase how our AI-powered multimodal analytics unblind tumor biology and accelerate drug development!

Read more: https://t.co/PWBmy9MR7I

[BostonGeneCorp @BostonGeneCorp]

BostonGene has been named a Platinum Winner for AI Research Innovation at the 2025 Pinnacle Awards, recognizing our AI-powered multiomic platform for advancing discovery, patient stratification and clinical trial optimization.

“We’re proud to receive this award, which highlights the impact of our platform in advancing therapeutic development. By integrating AI, multiomic profiling and real-world evidence, we enable drug developers to make smarter decisions—identifying responder populations, de-risking pipelines and shortening trial timelines. The result is a faster path to life-changing treatments for patients.” - Alexander Bagaev, PhD, Chief Product Officer at BostonGene

Read more: https://t.co/JgHkPQHTfp